Low Expression of BRCA1 as a Potential Relapse Predictor in B-Cell Acute Lymphoblastic Leukemia. 2023

Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
Experimental Oncology Laboratory.

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood hematological malignancy worldwide. Treatment outcomes have improved dramatically in recent years; despite this, relapse is still a problem, and the potential molecular explanation for this remains an important field of study. We performed microarray and single-cell RNA-Seq data mining, and we selected significant data with a P -value<0.05. We validated BRCA1 gene expression by means of quantitative (reverse transcription-polymerase chain reaction.) We performed statistical analysis and considered a P -value<0.05 significant. We identified the overexpression of breast cancer 1, early onset (BRCA1; P -value=2.52 -134 ), by means of microarray analysis. Moreover, the normal distribution of BRCA1 expression in healthy bone marrow. In addition, we confirmed the increases in BRCA1 expression using real-time (reverse transcription-polymerase chain reaction and determined that it was significantly reduced in patients with relapse ( P -values=0.026). Finally, we identified that the expression of the BRCA1 gene could predict early relapse ( P -values=0.01). We determined that low expression of BRCA1 was associated with B-cell acute lymphoblastic leukemia relapse and could be a potential molecular prognostic marker.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015452 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia. Leukemia, Pre-B-Cell,Pre-B-Cell Leukemia,Pre B-ALL,Pre-B ALL,Precursor B-Cell Lymphoblastic Leukemia,Precursor B-Cell Lymphoblastic Lymphoma,Leukemia, Pre B Cell,Leukemias, Pre-B-Cell,Pre B ALL,Pre B Cell Leukemia,Pre-B-Cell Leukemias,Precursor B Cell Lymphoblastic Leukemia,Precursor B Cell Lymphoblastic Leukemia Lymphoma,Precursor B Cell Lymphoblastic Lymphoma
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019313 BRCA1 Protein The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). It contains an N-terminal RING FINGER DOMAIN and is a PROTEIN PHOSPHATASE 1 regulatory subunit. In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91) BRCA1 Gene Product,Breast Cancer 1 Gene Product,Breast Cancer 1 Protein,Breast Cancer Type 1 Susceptibility Protein,Ring Finger Protein 53

Related Publications

Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
April 2001, Medical and pediatric oncology,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
August 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
April 2021, JAMA ophthalmology,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
January 1991, Leukemia research,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
February 1995, Blood,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
March 2024, Blood advances,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
March 2006, European journal of medical research,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
January 1998, International journal of cancer. Supplement = Journal international du cancer. Supplement,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
March 2010, International journal of dermatology,
Vanessa Villegas-Ruíz, and Isabel Medina-Vera, and Paulina Arellano-Perdomo, and Adriana Castillo-Villanueva, and Cesar A Galván-Diaz, and Rogelio Paredes-Aguilera, and Roberto Rivera-Luna, and Sergio Juárez-Méndez
July 2020, Medical science monitor : international medical journal of experimental and clinical research,
Copied contents to your clipboard!